# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Multi-Million-Dollar Investment Supports Hybrid And Electric Vehicle Advancements
JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $25 to $18.
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $30 to $28.
Barclays analyst Michael Leithead maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $30 to $22.
BMO Capital analyst John McNulty maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $35 to $30.
OutlookThe Company anticipates a low to mid-single digit sequential decline in Net Sales for the third quarter, reflective of:R...
Chemours (NYSE:CC) reported quarterly earnings of $0.38 per share which missed the analyst consensus estimate of $0.57 by 33.33...